Lawsuits are currently being filed against the makers of Dupixent, a medication taken to treat Eczema, Asthma and Nasal Polyps, alleging that the drug’s manufacturers, Sanofi and Regeneron, failed to adequately warn patients and doctors about the increased risk of Cutaneous T-Cell Lymphoma (CTCL) and other Lymphomas.
Lawsuits claim this failure led to delayed diagnoses and treatment for patients whose conditions were masked by the drug’s similar symptoms to eczema, potentially losing them valuable time for intervention.
Dupixent was developed by Regeneron Pharmaceuticals and Sanofi Genzyme and released in 2017. It is a monoclonal antibody used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.
The August 2024 issue of the Journal of the American Academy of Dermatology reported an increased risk of Cutaneous T–Cell Lymphoma (CTCL) was found in a cohort of atopic dermatitis patients who used dupilumab. The increased risk persisted after exclusion of prior disease–modifying antirheumatic drug
use. Risk was not increased for other cutaneous or lymphoid malignancies.
Espinosa et al. in July 2020 published a case review that found that long–term use (at least 3 months) of Dupixent leads to worsening or progression of CTCL. Other authors have published similar results
including Russomanno et al. 2021.
CTCL is a rare type of skin cancer that affects T lymphocytes, a type of white blood cell. Symptoms can include rashes and patches, plagues, lumps and tumors, discoloration, redness, thickened skin, swollen lymph nodes, hair loss, itching, fever and chills, unexplained weight loss, pain or tenderness, and night sweats.
There are several types of CTCL. The most common subtypes of CTCL are Mycosis fungoides and Sézary syndrome. Less common types include lymphomatoid papulosis, subcutaneous panniculitis-like T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, extranodal NK/T-cell lymphoma and primary cutaneous gamma/delta T-cell lymphoma.
Case Qualifications:
We are currently accepting cases that meet the following criteria:
1) Plaintiff was prescribed Dupixent and took it for at least one month.
2) Plaintiff was diagnosed with CTCL or one of its subtypes before or after receiving their first dose of Dupixent
There are several types of CTCL. The most common subtypes of CTCL are:
Mycosis fungoides
Sézary syndrome.
Less common types include:
Lymphomatoid Papulosis
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Primary Cutaneous Anaplastic Large Cell Lymphoma
Extranodal NK/T-Cell Lymphoma
Primary Cutaneous Gamma/Delta
“After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the Dupixent group. Dupixent was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for Dupixent users.”
Dupixent, also known by its generic name dupilumab, is a prescription drug approved by the FDA to treat conditions like:
It works by blocking certain proteins involved in inflammation. While many patients have found relief with Dupixent, some have reported devastating side effects — including the development or worsening of Cutaneous T-Cell Lymphoma, a rare but aggressive form of cancer.
For individuals who have been diagnosed with Cutaneous T–Cell Lymphoma (CTCL) after use of Dupixent, the potential for legal recourse is a critical consideration. Victims may be entitled to financial compensation to cover the following:
Cutaneous T-cell lymphoma (CTCL) is a rare type of skin cancer that affects white blood cells called T lymphocytes. It is a type of non-Hodgkin lymphoma.
Diagnosis
CTCL is diagnosed through a physical exam, skin biopsy, and blood tests.
Treatment
Treatment for CTCL depends on the stage of the disease and the patient’s overall health. Options may include:
Acceleration of cutaneous T-cell lymphoma following dupilumab administration
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study
Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis
